Safety of vedolizumab in liver transplant recipients

A systematic review

Marco Spadaccini, Alessio Aghemo, Flavio Caprioli, Ana Lleo, Federica Invernizzi, Silvio Danese, Maria F. Donato

Research output: Contribution to journalReview article

Abstract

Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.

Original languageEnglish
Pages (from-to)875-880
JournalUnited European Gastroenterology Journal
Volume7
Issue number7
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Safety
Liver
Inflammatory Bowel Diseases
Transplants
vedolizumab
Transplant Recipients
Biological Products
PubMed
Liver Transplantation
Physicians
Therapeutics
Infection
Neoplasms

Keywords

  • adverse events
  • inflammatory bowel disease
  • Liver transplantation
  • primary sclerosing cholangitis
  • vedolizumab

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Safety of vedolizumab in liver transplant recipients : A systematic review. / Spadaccini, Marco; Aghemo, Alessio; Caprioli, Flavio; Lleo, Ana; Invernizzi, Federica; Danese, Silvio; Donato, Maria F.

In: United European Gastroenterology Journal, Vol. 7, No. 7, 01.01.2019, p. 875-880.

Research output: Contribution to journalReview article

@article{f0541c097d9d4b77b8c023636dadac68,
title = "Safety of vedolizumab in liver transplant recipients: A systematic review",
abstract = "Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.",
keywords = "adverse events, inflammatory bowel disease, Liver transplantation, primary sclerosing cholangitis, vedolizumab",
author = "Marco Spadaccini and Alessio Aghemo and Flavio Caprioli and Ana Lleo and Federica Invernizzi and Silvio Danese and Donato, {Maria F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/2050640619858050",
language = "English",
volume = "7",
pages = "875--880",
journal = "United European Gastroenterology Journal",
issn = "2050-6406",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Safety of vedolizumab in liver transplant recipients

T2 - A systematic review

AU - Spadaccini, Marco

AU - Aghemo, Alessio

AU - Caprioli, Flavio

AU - Lleo, Ana

AU - Invernizzi, Federica

AU - Danese, Silvio

AU - Donato, Maria F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.

AB - Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.

KW - adverse events

KW - inflammatory bowel disease

KW - Liver transplantation

KW - primary sclerosing cholangitis

KW - vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85068161201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068161201&partnerID=8YFLogxK

U2 - 10.1177/2050640619858050

DO - 10.1177/2050640619858050

M3 - Review article

VL - 7

SP - 875

EP - 880

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 7

ER -